Literature DB >> 9893672

A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells.

Y Kanamori1, J Kigawa, Y Minagawa, T Irie, T Oishi, M Shimada, M Takahashi, T Nakamura, K Sato, N Terakawa.   

Abstract

A new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) was developed and the combination effect of p53 gene transfer and cis-diamminedichloroplatinum (II) (CDDP) was examined in an ovarian cancer cell line, SK-OV-3, with deletion of the p53 gene. AxCAp53 showed a high efficiency of gene transduction and increased sensitivity to CDDP in the SK-OV-3 cells. It was found that the sensitivity of the cells to CDDP correlated with the amount of infectious units of virus per cell of AxCAp53 which correlated with p53 protein expression. The results suggest that the combination of CDDP and AxCAp53 may be a potential strategy for the therapy of CDDP-resistant ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9893672     DOI： 10.1016/s0959-8049(98)00199-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  7 in total

1.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines.

Authors:  Sang Young Ryu; Kidong Kim; Woo Sik Lee; Hee Chung Kwon; Kee Ho Lee; Chang Min Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

3.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

4.  Telomerase activity and p53-dependent apoptosis in ovarian cancer cells.

Authors:  R Akeshima; J Kigawa; M Takahashi; T Oishi; Y Kanamori; H Itamochi; M Shimada; S Kamazawa; S Sato; N Terakawa
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

5.  Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways.

Authors:  Y Minagawa; J Kigawa; H Itamochi; Y Kanamori; M Shimada; M Takahashi; N Terakawa
Journal:  Jpn J Cancer Res       Date:  1999-12

6.  Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.

Authors:  Lei Wang; Shengyan Xiang; Kendra A Williams; Huiqin Dong; Wenlong Bai; Santo V Nicosia; Saadi Khochbin; Gerold Bepler; Xiaohong Zhang
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

7.  An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.

Authors:  Shoko Yoshida; Haruhiko Kawaguchi; Shigeki Sato; Ryuzo Ueda; Koichi Furukawa
Journal:  Jpn J Cancer Res       Date:  2002-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.